The Asymptomatic Outpatient with Abnormal Liver Function Tests

Clinics in Liver Disease

Volumn 13, Issue 2, 2009, Pages 167-177

  Krier, Michael ^a   Ahmed, Aijaz ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Albumin; Alkaline phosphatase; Aminotransferases (ALT and AST); LFT; Prothrombin time

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DANTROLENE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; KETOCONAZOLE; LACTATE DEHYDROGENASE; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PYRAZINAMIDE; RETINOID; SERUM ALBUMIN; STEROID; TACRINE; VALPROIC ACID; WARFARIN;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD DONOR; CHOLESTASIS; CONSULTATION; COST EFFECTIVENESS ANALYSIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GILBERT DISEASE; HEALTH INSURANCE; HEPATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MEDICAL PRACTICE; OUTPATIENT; PHYSICAL EXAMINATION; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; OUTPATIENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 65149091998     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.02.001     Document Type: Review

References (54)

1. Green R.M., and Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123 (2002) 1367-1384
2. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
3. Pratt D.S., and Kaplan M.M. Laboratory tests. In: Schiff E.R., Sorrell M.F., and Maddrey W.C. (Eds). Schiff's diseases of the liver vol. 1 (1999), Lippincott-Raven, Philadelphia 205-244
4. Kratz A., and Lewandrowski K.B. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med 339 (1998) 1063-1072
5. Friedman L.S., Martin P., and Munoz S.J. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D., and Boyer T.D. (Eds). Hepatology: a textbook of liver disease vol. 1 (1996), WB Saunders, Philadelphia 791-833
6. Sackett D.L.H.R., Guyatt G.H., and Tugwell P. Clinical epidemiology: a basic science for clinical medicine (1991), Little Brown, Boston
7. Henley K.S., Schmidt F.W., and Schmidt E. Newer diagnostic tests in liver disease. In: Popper H., and Schaffner F. (Eds). Progress in liver diseases vol. 1 (1961), Grune & Stratton, New York 216-228
8. Dufour D.R., Lott J.A., Nolte F.S., et al. Diagnosis and monitoring of hepatic injury. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring of hepatic injury. Clin Chem 46 (2000) 2050-2068
9. Bayraktar M., and Van Thiel D.H. Abnormalities in measures of liver function and injury in thyroid disorders. Hepatogastroenterology 44 (1997) 1614-1618
10. Begum T., Oliver M.R., Kornberg A.J., et al. Elevated aminotransferase as a presenting finding in a patient with occult muscle disease. J Paediatr Child Health 36 (2000) 189-190
11. Zamora S., Adams C., Butzner J.D., et al. Elevated aminotransferase activity as an indication of muscular dystrophy: case reports and review of the literature. Can J Gastroenterol 10 (1996) 389-393
12. Helfgott S.M., Karlson E., and Beckman E. Misinterpretation of serum transaminase elevation in "occult" myositis. Am J Med 95 (1993) 447-449
13. Siest G., Schiele F., Galteau M.-M., et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 21 (1975) 1077-1087
14. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 121 (2001) 710-723
15. Bacon B.R., Farahvash M.J., Janney C.G., et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107 (1994) 1103-1109
16. Fortson W.C., Tedesco F.J., Starnes E.D., et al. Marked elevation of serum transaminase activity associated with extrahepatic biliary tract disease. J Clin Gastroenterol 7 (1985) 502-505
17. Nyblom H., Berggren U., Balldin J., et al. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 39 (2004) 336-339
18. Sorbi D., Boynton J., and Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 94 (1999) 1018-1022
19. Berman D.H.L.R., Gavaler J.S., Cadoff E.M., et al. Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. Gastroenterology 100 (1991) 1129-1134
20. Sallie R., Katsiyiannakis L., Baldwin D., et al. Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure. Hepatology 16 (1992) 1206-1211
21. Giboney P.T. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 71 (2005) 1105-1110
22. Lazo M., Selvin E., and Clark J.M. Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med 148 (2008) 348-352
23. Manolio T.A., Burke G.L., Savage P.J., et al. Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. Clin Chem 28 (1992) 1853-1859
24. Bayer P.M., Hotschek H., and Knoth E. Intestinal alkaline phosphatase and the ABO blood group system: a new aspect. Clin Chim Acta 108 (1980) 81-87
25. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med 117 (1993) 187-190
26. Yamada N., Kido K., Hayashi S., et al. Characteristics of blood biochemical constituents of pregnant women. Acta Obstet Gynaecol Jpn 29 (1977) 447-450
27. Dufour D.R. Effects of oral contraceptives on routine laboratory tests. Clin Chem 44 (1998) (Suppl 6):A137.
28. Seetharam S., Sussman N.L., Komoda T., et al. The mechanism of elevated alkaline phosphatase activity after bile duct ligation in the rat. Hepatology 6 (1986) 374-380
29. McGarrity T.J., Samuels T., and Wilson F.A. An analysis of imaging studies and liver function tests to detect hepatic neoplasia. Dig Dis Sci 32 (1987) 1113-1137
30. Hedworth-Whitty R.B., Whitfield J.B., and Richardson R.W. Serum gamma-glutamyltranspeptidase activity in myocardial ischaemia. Br Heart J 29 (1967) 432-438
31. Penn R., and Worthington D.J. Is serum gamma-glutamyltransferase a misleading test?. Br Med J 286 (1983) 531-535
32. Zimmerman H.J. Intrahepatic cholestasis. Arch Intern Med 139 (1979) 1038-1045
33. Scharschmidt B.F., Blanckaert N., Farina F.A., et al. Measurement of serum bilirubin and its mono- and diconjugates: application to patients with hepatobiliary disease. Gut 23 (1982) 643-649
34. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001) 464-470
35. Wiesner R., Edwards E., Freeman R., et al. The United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
36. Fuchs S., Bogomolski-Yahalom V., Paltiel O., et al. Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol 26 (1998) 183-186
37. Singer A.J., Carracio T.R., and Mofenson H.C. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 26 (1995) 49-53
38. Willner I.R., Uhl M.D., Howard S.C., et al. Serious hepatitis A: an analysis of patients hospitalized during an epidemic in the United States. Ann Intern Med 128 (1998) 111-114
39. Mendenhall C.L., and VA Cooperative Study Group on Alcoholic Hepatitis. Alcoholic hepatitis. Clin Gastroenterol 10 (1981) 417-441
40. O'Grady J.G., Alexander G.J., Hayllar K.M., et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439-445
41. Kovacs M.J., Wong A., MacKinnon K., et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 71 (1994) 727-730
42. Denson K.W., Reed S.V., and Haddon M.E. Validity of the INR system for patients with liver impairment. Thromb Haemost 73 (1995) 162
43. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2000) 1266-1271
44. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
45. Patt C.H., Yoo H.Y., Dibadj K., et al. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci 48 (2003) 797-801
46. Christoffersen P., and Petersen P. Morphological features in noncirrhotic livers from patients with chronic alcoholism, diabetes mellitus or adipositas. A comparative study. Acta Pathol Microbiol Scand [A] 86A (1978) 495-498
47. Tominaga K., Kurata J.H., Chen Y.K., et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 40 (1995) 2002-2009
48. Boulton R., Hamilton M.I., Dhillon A.P., et al. Subclinical Addison's disease: a cause of persistent abnormalities in transaminase values. Gastroenterology 109 (1995) 1324-1327
49. Bardella M.T., Vecchi M., Conte D., et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 29 (1999) 654-657
50. Conigrave K.M., Degenhardt L.J., Whitfield J.B., et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 26 (2002) 332-339
51. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N Engl J Med 354 (2006) 731-739
52. Ostapowicz G., and Lee W.M. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol 15 (2000) 480-488
53. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
54. Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126 (2004) 1287-1292